Stock Market Reviews

BOLT (Bolt Biotherapeutics, Inc.) News

Get the latest news, insights, and market updates on BOLT (Bolt Biotherapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot
  BOLT) on Wednesday reported a loss of $7.1 million in its third quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of $3.72. The results exceeded Wall Street expectations.
  Nov 12, 2025 - $BOLT
• Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
  Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 12, 2025 - $BOLT
• Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
  Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “In
  Nov 12, 2025 - $BOLT
• Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
  Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Nov 4, 2025 - $BOLT
• Sector Update: Health Care Stocks Retreat Late Afternoon
  Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index shedding 0.4% a
  Oct 2, 2025 - $BOLT
• Washington Shutdown Continues as US Equity Futures Trade Mixed Ahead of Opening Bell
  US equity futures were mixed ahead of Thursday's opening bell as the federal government shutdown ent
  Oct 2, 2025 - $BOLT
• Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
  Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candid
  Oct 1, 2025 - $BOLT
• Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot
  BOLT) on Thursday reported a loss of $8.6 million in its second quarter. The Redwood City, California-based company said it had a loss of $4.46 per share. The company posted revenue of $1.8 million in the period.
  Aug 14, 2025 - $BOLT
• Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
  Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +30.31% and +73.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 14, 2025 - $BOLT
• Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
  Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “In the sec
  Aug 14, 2025 - $BOLT